Shortfall in Knowledge of Treatment Optimization for Castration-Resistant Prostate Cancer

Prostate cancer is the tumor type with highest incidence in men in the United States. Typically, the first line treatment for progressive disease is androgen deprivation therapy (ADT). However, most men eventually stop responding to ADT treatment and develop castration-resistant prostate cancer (CRPC). The therapeutic options for this highly heterogeneous disease process have expanded to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metasta...
Continue reading

Castration-Resistant Prostate Cancer: Guiding Patients Through Treatment With Brenda Martone, MSN, ANP-BC, AOCNP

‚ÄčAndrogen deprivation therapy is a cornerstone of treatment for progressive prostate cancer, but over time, many patients stop responding to this treatment, developing a resistance to castration. Until recently, nonmetastatic castration-resistant prostate cancer (CRPC) lacked effective treatment options; this situation has changed dramatically with the rise of several new agents. Metastatic CRPC is the primary cause of prostate-related mortality, yet advances in treatment are extending survival....
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.